Sulforaphane, a cruciferous vegetable-derived isothiocyanate, inhibits protein synthesis in human prostate cancer cells  by Wiczk, Aleksandra et al.
Biochimica et Biophysica Acta 1823 (2012) 1295–1305
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrSulforaphane, a cruciferous vegetable-derived isothiocyanate, inhibits protein
synthesis in human prostate cancer cells
Aleksandra Wiczk, Dagmara Hofman, Grażyna Konopa, Anna Herman-Antosiewicz ⁎
Department of Molecular Biology, University of Gdańsk, Kładki 24, 80‐822 Gdańsk, Poland⁎ Corresponding author. Tel.: +48 58 523 6317; fax:
E-mail address: wuzel@biotech.ug.gda.pl (A. Herman
0167-4889/$ – see front matter © 2012 Elsevier B.V. All
doi:10.1016/j.bbamcr.2012.05.020a b s t r a c ta r t i c l e i n f oArticle history:
Received 20 January 2012
Received in revised form 17 May 2012
Accepted 18 May 2012
Available online 25 May 2012
Keywords:
Sulforaphane
Prostate cancer
mTOR
S6K1
Protein synthesis
SurvivinSulforaphane (SFN) is a compound derived from cruciferous plants. Its anticancer properties have been dem-
onstrated both, in cancer cell lines as well as tumors in animal models. It has been shown that SFN inhibits
cell proliferation, induces apoptosis, autophagy, and sensitizes cancer cells to therapies. As induction of cat-
abolic processes is often related to perturbation in protein synthesis we aimed to investigate the impact of
SFN on this process in PC-3 human prostate cancer cells. In the present study we show that SFN inhibits pro-
tein synthesis in PC-3 cells in a dose- and time-dependent manner which is accompanied by a decreased
phosphorylation of mTOR substrates. Translation inhibition is independent of mitochondria‐derived ROS as
it is observed in PC-3 derivatives devoid of functional mitochondrial respiratory chain (Rho0 cells). Although
SFN affects mitochondria and slightly decreases glycolysis, the ATP level is maintained on the level character-
istic for control cells. Inhibition of protein synthesis might be a protective response of prostate cancer cells to
save energy. However, translation inhibition contributes to the death of PC-3 cells due to decreased level of a
short-lived protein, survivin. Overexpression of this anti-apoptotic factor protects PC-3 cells against SFN cy-
totoxicity. Protein synthesis inhibition by SFN is not restricted to prostate cancer cells as we observed similar
effect in SKBR-3 breast cancer cell line.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Epidemiologic studies showed that high level cruciferous vegeta-
ble intake may lower the risk of cancer, including prostate cancer
[1–5]. Isothiocyanates are the main chemopreventive constituents of
these plants. They are generated by hydrolysis of their precursors,
glucosinolates. One of the best studied isothiocyanate, abundant in
broccoli and broccoli sprouts, is sulforaphane [1-isothiocyanato-4-
(methyl-sulﬁnyl)butane], SFN. It was identiﬁed in 1992 as a potent
chemopreventive agent able to induce Phase 2 detoxiﬁcation en-
zymes [6]. Later, it was shown that SFN also acted as an inhibitor of
enzymes involved in carcinogen activation [7]. Subsequent numerous
studies demonstrated that SFN blocked cancer development at post-
initiation phases as well, inhibiting proliferation and inducing cancer
cell apoptosis [8,9]. Among reported mechanisms underlying antican-
cer activity of SFN there are: oxidative stress induction [10–12], DNA
damage checkpoint activation [13], inhibition of histone deacetylases
[14,15] or direct binding to cellular proteins, such as tubulins [16].
Importantly, signaling pathways induced in cancer cells by SFN
might depend on its dose. For instance, Yeh and Yen observed that
low SFN concentrations (up to 20 μM) induced MAPK-mediated acti-
vation of Nrf-2 transcription factor, thus a protective response. On the+48 58 523 6424.
-Antosiewicz).
rights reserved.other hand, higher SFN concentrations (30–100 μM) induced apopto-
sis of HepG2 cells [17].
Prostate cancer is one of the most extensively studied models of
SFN anticancer activity. It was demonstrated that oral administration
of SFN retarded the growth of PC-3 human prostate xenografts in ath-
ymic mice and inhibited prostate carcinogenesis and pulmonary me-
tastasis in transgenic mouse model of prostate cancer [18,19]. Based
on in vitro studies using different human prostate cancer cell lines,
it was shown that SFN-induced oxidative stress is caused by depletion
of glutathione and elevation of reactive oxygen species (ROS) produc-
tion by mitochondria which led to a drop in mitochondrial membrane
potential, release of cytochrome c and caspase-dependent cell death.
Antioxidants (N-acetylcysteine or mimetic of superoxide dismutase
and catalase, EUK134) or overexpression of catalase signiﬁcantly
protected the cells against SFN-induced ROS generation and apoptosis
[12]. It was later shown that mitochondria-derived ROS are generated
due to inhibition of respiratory chain complexes by SFN in prostate
cancer cells. Their derivatives devoid of mitochondrial DNA (Rho0
cells) were signiﬁcantly more resistant to SFN-induced ROS genera-
tion, G2/M cell cycle arrest and apoptosis than wild type cells [10]. In-
terestingly, pro-survival autophagy observed in PC-3 and LNCaP cells
treated with SFN was partially but not fully suppressed in Rho0 cells
[10].
Protein synthesis is essential for cell viability and proliferation.
Translation initiation is a common downstream target of signal trans-
duction pathways deregulated in human cancers due to activation of
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in these pathways [20]. For example, positive regulator of translation,
the Akt kinase, is overactive in many human cancers, including carci-
nomas, glioblastoma multiforme and various hematological malig-
nancies (reviewed in [21]). mTOR (the mammalian target of
rapamycin) is a crucial regulator of translation, which together with
associated proteins, raptor and mLST8 (GβL), phosphorylates the
eukaryotic initiation factor 4E-binding protein (4E-BP), an inhibitor
of cap-dependent translation, and the p70S6 kinase1 (S6K1) [22].
S6K1 plays a pleiotropic role in translation. For a long time it was be-
lieved that S6K1 participates in ribosomal biogenesis through activa-
tion of ribosomal protein S6 (RPS6). Other known S6K1 substrates
include eukaryotic elongation factor 2 kinase (eEF2K) and eukaryotic
translation initiation factor 4B (eIF4B) [23–25]. Thus, S6 kinase1 con-
trols important stages of translation and its targeting should have
detrimental effect on cancers that are dependent on the elevated
rate of protein synthesis.
In the present study we demonstrate that protein synthesis inhibi-
tion is another mechanism of SFN activity. It is independent of
mitochondria-derived ROS, occurs very early after SFN administration
and is accompanied by a decreased mTOR-S6K1-S6 signaling. Al-
though translation inhibition may contribute to ATP level mainte-
nance, and thus become a protective response of cancer cells to SFN,
it ﬁnally leads to depletion of short-lived survivin, the protein crucial
for survival of prostate cancer cells.
2. Materials and methods
2.1. Reagents
D,L-SFN (purity 99%) was purchased from LKT Laboratories (St.
Paul, MN). Tissue culture media, penicillin/streptomycin antibiotic
mixture and fetal bovine serum were from GIBCO (Grand Island,
NY). [3H]-leucine was from Perkin Elmer (Waltham, MA). The anti-
bodies against p-AMPK (Thr-172), p-Akt (Ser-473) and Akt were
from Santa Cruz Biotechnology (Santa Cruz, CA), p-S6K1 (Thr-389),
S6K1, p-S6 (Ser-235/236), ribosomal S6, survivin, PARP, 4E-BP,
AMPK, calyculin A and rapamycin were from Cell Signaling Technolo-
gy (Danvers, MA), the anti-β-actin, anti-GAPDH, anti-mouse and anti-
rabbit antibodies conjugated with HRP, as well as DMSO, oligomycin,
MG132 and PF-4708671 were from Sigma-Aldrich (St. Louis, MO).
The plasmid encoding survivin was from Dr. Ritu Aneja, Department
of Biology, Georgia State University, Atlanta.
2.2. Cell lines and Rho0 cell generation
Monolayer cultures of PC-3 or SKBR-3 cells weremaintained in F12-
K nutrient mixture medium or RPMI1640 medium, respectively, sup-
plementedwith 10% (v/v) fetal bovine serum and antibiotics. Rho0 var-
iant of PC-3 cells (depleted of mitochondrial DNA) was generated by
culturing cells for 8 weeks with 100 ng/ml ethidium bromide in com-
plete medium supplemented with 4.5 mg/ml glucose, 100 μg/ml sodi-
um pyruvate and 50 μg/ml uridine to compensate for the respiratory
metabolism deﬁcit as previously described [26]. To verify the mtDNA
depletion, total cellular DNA was isolated and subjected to PCR using
primers for mitochondrial ND5 gene coding for NADH dehydrogenase
subunit 5 (forward: TTCATCCCT GTAGCATTGTTCG and reverse:
AGCGGATGAGTAAGAAGATTCC)which gives a 522 bp product. For con-
trol, fragment of the chromosomal GAPDH genewas ampliﬁed. Each cell
linewasmaintained at 37°C in a humidiﬁed atmospherewith 5%CO2. D,
L-sulforaphane was prepared in DMSO and stored at a stock concentra-
tion of 10 mMat−20°C. Doses applied in this work (10, 20 and 40 μM)
have been previously tested on PC-3 cell line as the most effective
[10,12,13,27]. To inhibit PP1 and PP2A phosphatases or mTOR kinase
calyculin A (ﬁnal concentration 1 nM or 100 nM) or rapamycin (ﬁnal
concentration 100 nM)were added 30 min or 1 h before SFN treatment,respectively. To inhibit proteasome, MG132 (ﬁnal concentration 1 μM)
was added 2 h before SFN treatment.2.3. Protein synthesis assay
Cells (1.5×105/well) were cultured in 12-well plates and treated
with SFN (40 μM for indicated times or 10, 20, 40 μM SFN for 3 h)
and 2 μCi/well L-[3, 4, 5-3H]-leucine. Both, ﬂoating and attached
cells were collected, ﬁxed in 5% TCA at room temperature for
30 min and washed with 5% TCA for 15 min. The acid-insoluble mate-
rial was dissolved in 0.1 mol/L KOH overnight at 4°C and aliquots
were used to determine the radioactivity using liquid scintillation
counter (Beckman LS3133P). Radioactivity of samples was normal-
ized to cell number.2.4. Transmission electron microscopy
Transmission electron microscopy to compare ultrastucture of pa-
rental PC-3 cells and their Rho0 derivatives was performed essentially
as described previously [12,27]. Brieﬂy, cells (1.5×105) were plated
in 12-well plates, and allowed to attach overnight. The cells were
ﬁxed in ice-cold 2.5% electron microscopy grade glutaraldehyde in
0.1 M PBS (pH 7.3). The specimens were rinsed with PBS, post-ﬁxed
in 1% osmium tetroxide with 0.1% potassium ferricyanide, dehydrated
through a graded series of ethanol (30–100%), and embedded in
Epon, Fluka (USA). Semi-thin (300 nm) sections were cut using an
RMC Power Tome XL Reichart Ultracut, stained with 0.5% toluidine
blue and examined under a light microscope. Ultrathin sections
(65 nm) were stained with 2% uranyl acetate and Reynold's lead
citrate, and examined on a Philips CM100 transmission electron
microscope.2.5. Immunoblotting
Cells were treated with SFN and lysed using a solution containing
50 mM Tris, 1% Triton X-100, 150 mM NaCl, 0.5 mM EDTA, protease
and phosphatase inhibitor cocktails (Roche Diagnostics, Germany).
Lysates were cleared by centrifugation at 13,000 rpm for 20 min. Pro-
teins were resolved by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto PVDF membrane. The membrane was
blocked with 5% non-fat dry milk in phosphate buffered saline, and
incubated with the desired primary antibody overnight at 4 °C. The
membrane was treated with appropriate secondary antibody for 1 h
at room temperature. The immunoreactive bands were detected
with an enhanced chemiluminescence reagent (Thermo Scientiﬁc
Pierce, Rockford, IL). The blots were stripped and reprobed with
anti-β-actin or anti-GAPDH antibodies. The change in protein level
was determined by densitometric analysis of the immunoreactive
bands by Quantity One software (BioRad) followed by correction for
the respective loading control. The immunoblotting for each protein
was performed at least twice using independently prepared lysates.2.6. Measurement of ROS generation
Intracellular ROS generation in DMSO-treated control and SFN-
treated cells (40 μM SFN for 4 h) was measured by ﬂow cytometry
following staining with H2DCFDA, which is cleaved by nonspeciﬁc
cellular esterases and oxidized in the presence of H2O2 and peroxi-
dases to ﬂuorescent 2′,7′-dichloroﬂuorescein (DCF). Brieﬂy, cells
(5×105) were plated in 60 mm dishes, allowed to attach overnight,
and treated with DMSO or SFN for 4 h. Cells were exposed to 5 mM
H2DCFDA for the last 30 min of incubation, collected and ﬂuorescence
was measured using a FACScan cytometer (Becton Dickinson, USA).
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ATP level was determined using the ATP Bioluminescence Assay
Kit HS II (Roche Diagnostics) according to manufacturer recommen-
dations. Brieﬂy, cells were cultured in 12-well plates and treated
with 40 μM SFN for indicated times. Both ﬂoating and attached cells
were collected, resuspended and lysed. Aliquots were transferred to
black 96-well plates and luciferase was added. The luminescence
was measured in Victor3 microplate reader.
2.8. Lactate determination
L(+)-lactate level in PC-3 cells was determined using the Lactate
Assay Kit (MBL International) according to the manufacturer instruc-
tion. Brieﬂy, 1×106 cells were plated and allowed to attach overnight.
The following day, cells were treated with 40 μM SFN for indicated
time or treated with vehicle (control). Both, ﬂoating and attached
cells were collected and washed with ice-cold PBS. Cell pellet was
suspended in 250 μl of ice-cold Lactate Assay Buffer and homogenized
by sonication. Samples were centrifuged (13,000 rpm, 20 min) and
obtained supernatant was used for subsequent assays.
2.9. Reverse transcription quantitative real-time PCR
Cells (5×105) were plated in 6-well plates, allowed to attach over-
night and next day treated with 40 μM SFN or vehicle (DMSO) for 3 or
24 h. Both ﬂoating and attached cells were collected and washed with
ice-cold PBS. Total RNAwas isolated using Total RNAMini kit (A&A Bio-
technology) according to the manufacturer's instructions. A 0.5 μg of
total RNA was used for ﬁrst-strand cDNA synthesis using random
hexamer primers and RevertAid™ HMinus Reverse Transcriptase (Fer-
mentas). Real-time PCR was performed on LightCycler® 2.0 (Roche Ap-
plied Science) using Real-Time 2× HS-PCR Master Mix Probe (A&A
Biotechnology) and probes (Roche Applied Science) according to man-
ufacturers' instructions. Speciﬁc primers and a probe for survivin gene
were designed using the ProbeFinder software (RocheApplied Science),
and were as follows: sense 5′-CACCGCATCTCTACATTCAAGA-3′; anti-
sense 5′-CAAGTCTGGCTCGTTCTCAGT-3′; probe #86. Primers and
probe for the reference gene coding for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were purchased from Roche Applied Science.
The 2−ΔΔct method was used to determine the relative survivin tran-
script levels after normalization to the reference gene (GAPDH).
2.10. Transient transfection with survivin-encoding plasmid
Cells were transfected with empty vector pcDNA3 or vector
encoding survivin using TurboFect (Fermentas) according to the
manufacturer's recommendations. After 24 h cells were treated with
DMSO (vehicle) or 40 μM SFN for 24 h and cell viability, morphology
and apoptosis induction (PARP cleavage) was determined. Cell viabil-
ity was measured using WST1 assay for PC-3 cells growing in a 96-
well plate (starting density 8×103/well). WST1 solution was added
for the last 1 h of incubation. The absorbance was measured at
490 nm in Victor3 microplate reader. Morphology of cells transfected
with empty vector or plasmid encoding survivin, treated with DMSO
or 40 μM SFN was examined under a light microscope.
2.11. Statistical analysis
Data were analyzed using GraphPad Prism software. T-test or one-
way ANOVA followed by Bonferroni's or Dunnett's multiple compari-
son test was used to determine statistical signiﬁcance of difference in
measured variables between control and treated group or between
groups, respectively. Difference was considered signiﬁcant at Pb0.05.3. Results
3.1. Sulforaphane decreases protein synthesis in PC-3 cells
It has been previously shown that SFN inhibits proliferation of
PC-3 cells in a time- and dose-dependent manner [18] and induces
protective response, autophagy [27]. As cell growth inhibition and
especially induction of catabolic processes, such as autophagy, are
often related to perturbations in protein synthesis, we tested if SFN af-
fects translation in prostate cancer cells. We measured [3H]-leucine in-
corporation in control, DMSO-treated cells, and cells exposed to 40 μM
SFN for different times (5, 15, 30 min or 1, 2 and 3 h). As demonstrated
in Fig. 1A, SFN inhibited [3H]-leucine incorporation which was evident
already after 1-hour treatment. Protein synthesis measured after 3-hour
exposure to SFN was inhibited in a dose-dependent manner and in sam-
ples treated with 10, 20 or 40 μMSFN it dropped to about 80, 60 and 30%
of the level seen in control cells, respectively (Fig. 1B). We also deter-
mined the effect of longer time treatment with SFN on protein synthesis.
As shown in Fig. 1C, [3H]-leucine incorporation in cells treated with
40 μM SFN for 6, 16 or 24 h is statistically signiﬁcantly lower than in
respective control cells which indicates persistent translation block.
3.2. Protein synthesis block correlates with the inhibition of mTOR signal-
ing by SFN
As translation is primarily controlled by mTOR kinase we deter-
mined the effect of SFN on phosphorylation of mTOR substrates, S6
kinase1 and 4E-BP. As shown in Fig. 2A, SFN (40 μM) treatment caused
a time-dependent decrease in phosphorylation of S6K1 at Thr-389, po-
sition phosphorylated bymTOR [28]. This effectwas seen very early: the
amount of p-S6K1 dropped by about 20% or 50% of the level in control
cells after 15 and 30 min of exposure to SFN, respectively. In cells treat-
ed for longer times (up to 3 h), phosphorylation of S6K1 at Thr-389was
kept at low level, corresponding to 10–20% of that in DMSO-treated
samples. At the same time, changes in total level of S6K1 were not sig-
niﬁcant (Fig. 2A). In our model dephosphorylation of S6K1 correlated
with a drop in Ser-235/236 phosphorylation of S6, the substrate of
S6K1. It was evident after 1-hour treatment while changes in the total
S6 level over time were not signiﬁcant (Fig. 2A). Changes in S6K1 and
S6 phosphorylation status were dependent on the SFN concentration:
3 h of treatmentwith 10, 20 or 40 μMSNF reduced threonine-389 phos-
phorylation of S6K1 to about 40, 30 and 10% of the control level, respec-
tively, and serines — 235/236 phosphorylation of S6 to 70, 50 or 30%,
respectively (Fig. 2B). Dephosphorylation of 4E-BP, another mTOR sub-
strate, was observed as a drop in intensity of bands corresponding to
phosphorylated (γ, upper band) and an increase in intensity of
unphosphorylated (α, lower band) forms of the protein which was de-
pendent on treatment time and dose of SFN (Fig. 2A and B).
3.3. SFN-induced dephosphorylation of S6K1 is mediated by mTOR sig-
naling but not by calyculin A-sensitive protein phosphatases
Activation of S6K1 requires phosphorylations at multiple sites, such
as series of serines and threonines in the C-terminal regulatory domain
by ERK1/2, JNK1/2 or CDK1, Thr-229 in catalytic domain by PDK1, and
Thr-389 in the kinase extension domain by mTOR [28,29]. Thus, status
of Thr-389 of S6K1 is often regarded as a marker of mTOR activity. On
the other hand, this position is dephosphorylated by class PP1 or PP2A
phosphatases [30]. To elucidate which signaling pathway is affected
by SFN, ﬁrst we pretreated PC-3 cells with 1 nM calyculin A which in-
hibits PP1 and PP2A serine/threonine phosphatases. As demonstrated
in Fig. 3A, 1 nM calyculin A had no effect on SFN induced dephosphory-
lation of S6K1, which might indicate that the observed drop in S6K1
phosphorylation is not due to enhanced phosphatases activity or that
1 nM inhibitor concentration is too low, thus not effective. On the
other hand 1 nM calyculin A partially protected against SFN-induced
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Fig. 1. SFN inhibits protein synthesis in human prostate cancer cells. PC-3 cells were
treated with 40 μM SFN for indicated times (A and C) or with various concentrations
of SFN for 3 h (B) in the presence of a protein precursor, [3H]‐leucine. Cells were
harvested and radioactivity of TCA-precipitable material was estimated as described
in Materials and methods. Results shown are mean±SE of two (A and C) or three
(B) independent experiments. In A and C *signiﬁcantly different (Pb0.05) compared
with respective DMSO-treated control by Student's t test. In B *signiﬁcantly different
(Pb0.01) compared with DMSO-treated control by one-way ANOVA followed by Dun-
nett's multiple comparison test.
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strate of calyculin A sensitive phosphatases [31,32]. Different sensitivity
of p-S6K1, p-S6 and p-Akt to calyculin Amay be due to a different afﬁn-
ity of calyculin A-sensitive phosphatases to the respective substrates.
Moreover, compensating phosphorylation of S6 by RSK has been
reported in cells devoid of S6 kinases expression [33]. However, partial
S6 phosphorylation in PC-3 cells treated with 1 nM calyculin A did not
suppress SFN-induced block in protein synthesis (Fig. 3B). Higher cal-
yculin A concentration (100 nM) protected against SFN-induced S6K1
and S6 dephosphorylation, as well as caused accumulation of another
PP2A substrate, Akt kinase phosphorylated at Ser-473 (Fig. 3A).However, it induced massive cell detachment and proliferation block,
as incorporation of [3H]-leucine was completely inhibited (Fig. 3B).
Next, we tested a hypothesis that SFN-induced drop in p-S6K1 is due
to the mTOR-S6K1 signaling perturbation. PC-3 cells were treated with
40 μM SFN for 1.5 h and released to fresh mediumwith either DMSO or
rapamycin (100 nM) for 1, 3 or 6 h. Rapamycin is a speciﬁc inhibitor of
mTOR complex 1 which targets, among others, the S6 kinase1 at Thr-
389 position [28,29]. SFN treatment caused dephosphorylation of
S6K1 and its target, S6 (Fig. 3C). After release to controlmedium,we ob-
served a gradual increase in phospho-forms of investigated proteins.
However, SFN-induced hypophosphorylation of S6K1 and S6 was
maintained in cells released to medium containing rapamycin. It indi-
cates that in this model S6K1 phosphorylation at analyzed position is
not mediated by any other kinase except frommTOR. Thus, SFN inhibits
mTOR-mediated S6K1 phosphorylation (Fig. 3C).
3.4. Effect of SFN on protein synthesis is independent of mitochondria-
derived reactive oxygen species
It has been previously demonstrated that SFN inhibits mitochon-
drial respiratory chain complexes in prostate cancer cells. It leads to
generation of ROS by mitochondria and they play a crucial role in in-
ducing cell cycle arrest and apoptosis [10,12]. To determine if
mitochondria-derived ROS are necessary for translation inhibition
we used Rho0 variant of PC-3 cells. Cells were obtained by culturing
in the presence of ethidium bromide and supplements which allow
cells to produce ATP at proper level through glycolysis. Lack of mito-
chondrial DNA was veriﬁed by ampliﬁcation of mitochondrial ND5
gene coding for NADH dehydrogenase subunit 5 (Fig. 4A) and mor-
phology of Rho0 and parental cells by transmission electron micros-
copy (Fig. 4B). Presence of lipid droplets is characteristic of Rho0
cells due to impaired β-oxidation of fatty acids. Mitochondria of
Rho0 cells have alteredmorphology and reduced cristae content com-
pared to wild type organelle, which is consistent with the earlier re-
ports [34]. We compared ROS level in PC-3 and Rho0 cells upon
DMSO or SFN (40 μM) treatment. As expected, Rho0 cells were resis-
tant to SFN-induced ROS formation evaluated as a mean ﬂuorescence
of DCF, which is in agreement with previously reported data for
20 μM SFN [10] (Fig. 4C). Interestingly, lack of mitochondria-derived
ROS did not protect Rho0 cells from protein synthesis inhibition by
SFN (Fig. 4D) and dephosphorylation of S6K1 and S6 proteins
(Fig. 4E) indicating that effect of SFN on translation is independent
of mitochondria-derived ROS.
3.5. Effect of SFN on energy status of PC-3 cells
As SFN inhibits enzymes of mitochondrial respiratory chain com-
plexes I, II and III in prostate cancer cells [10], we hypothesized that
it might lead to a drop in ATP level which impacts mRNA translation
through AMPK-mTOR signaling. We looked at AMPK catalytic subunit
which is phosphorylated at Thr-172 when the AMP:ATP ratio in-
creases in the cells. Interestingly, SFN-induced changes in phospho-
AMPK within the ﬁrst minutes of the treatment were not signiﬁcant.
Longer treatment time caused a decrease in AMPK phosphorylated at
Thr-172 which was statistically signiﬁcant after 1-hour exposure to
SFN (Fig. 5A). We were not able to detect any changes in ATP level
measured in lysates of cells treated for various times with SFN, al-
though inhibitor of mitochondrial respiration (oligomycin) modestly
and inhibitor of glycolysis (deoxyglucose) statistically signiﬁcantly
decreased ATP level (Fig. 5B). Perturbation in mitochondrial ATP pro-
duction might be compensated by elevated glycolysis. To test this
possibility, we measured lactate production by control or SFN-
treated cells. As demonstrated in Fig. 5C, there was no upregulation
of glycolysis rate by SFN, rather a slight decrease (not statistically sig-
niﬁcant) in lactate production was observed. Altogether, these results
indicate that even if SFN perturbs ATP production, the decrease in its
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treated control by one-way ANOVA followed by Dunnett's multiple comparison test.
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thesis compensates for eventual drop in ATP.
3.6. SFN-induced survivin depletion contributes to decreased survival of
PC-3 cells
Translation inhibition may cause depletion of short-lived proteins
that are essential for cell survival. One of them is survivin, an inhibitorof apoptosis and mitosis regulator. It is often overexpressed in cancer
cells, including prostate cancers, which is controlled by mTOR-S6K1
pathway. We determined the effect of SFN on survivin level in PC-3
cells. As shown in Fig. 6A, SFN in a dose-dependent manner decreased
survivin level, and in cells treated with 40 μM SFN this drop was evi-
dent after 1 h of treatment and was maintained till 24 h (Fig. 6A). To
determine if the observed changes in survivin level are due to de-
creased gene expression, we evaluated survivin mRNA level in control
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for 2 h and processed for radioactivity measurement (B). Results shown are mean±SE
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PCR. As demonstrated in Fig. 6B, 3-hour treatment with 40 μM SFN
had no signiﬁcant effect on survivin gene transcription as compared
to control cells. To elucidate if decreased survivin level is due to
enhanced proteasome activity we used a proteasome inhibitor,
MG132. As shown in Fig. 6C, MG132 only partially protected against
SFN-induced drop in survivin protein level. To conﬁrm that in PC-3
cells survivin synthesis is controlled by mTOR and S6K1 we used spe-
ciﬁc inhibitors of these kinases, rapamycin and PF-470867, respec-
tively. Treatment with 100 nM rapamycin for 3 h or 10 μM PF-
470867 for 2 h caused a signiﬁcant drop in survivin level (Fig. 6D).
To assess a possible link between survivin downregulation and
survival of cells treated with SFN, we transiently transfected PC-3
cells with a plasmid encoding survivin and cell viability was assessed
by the WST1 method. Viability of cells transfected with empty vector
decreased after 24-hour treatment with 40 μM SFN by 50% compared
with DMSO-treated cells (Fig. 6E). Interestingly, cells expressing
higher amounts of survivin showed enhanced viability compared
with cells expressing only endogenous survivin, which was also ob-
served in SFN-treated cells: their survival decreased by about 30%
compared with DMSO-treated survivin overexpressing cells, and
still it was 100% higher than SFN-treated cells expressing only endog-
enous survivin. Similar effect of survivin overexpression was evident
when morphology of cells was compared in phase contrast microsco-
py (Fig. 6F). Protective role of survivin was due to apoptosis inhibi-
tion, as assessed by PARP cleavage, which is a marker of caspase-3
and caspase-7 activity. As shown in Fig. 6G, additional pool of sur-
vivin, even if decreased upon SFN treatment, protected against PARP
cleavage by caspases.
3.7. SFN-induced protein synthesis block is not limited to PC-3 prostate
cancer cells
To reconcile if translation inhibition by SFN is limited to prostate can-
cer cells or is a more general phenomenon we used a cell line derived
from breast cancer, SKBR-3. Protein synthesis measured as [3H]-leucine
incorporation was inhibited by SFN in a dose dependentmanner: 10, 20
or 40 μMSFN caused a drop in protein synthesis to about 80, 50 and 20%
of the level seen in control cells, respectively (Fig. 7A). Similarly to pros-
tate cancer cells, translation inhibition was accompanied by a decreased
mTOR-S6K1-S6 signaling detected as a dephosporylation of S6K1 at Thr-
389 and its substrate, ribosomal S6 at Ser-235/236 (Fig. 7B).
4. Discussion
Sulforaphane has been shown to inhibit proliferation of prostate
cancer cells inducing G2/M cell cycle arrest and subsequent apoptosis
[12,13,18]. It also activated protective autophagy [27]. In this work we
show that SFN blocks protein synthesis in different cancer cells, PC-3
prostate cancer cell line and SKBR-3 breast cancer cell line. In PC-3
cells it is an early event, evident after 1-hour treatment with 40 μM
drug, thus it is not a result of cell proliferation inhibition (Fig. 1A).
The master regulator of translation is mTOR kinase. It is stimulated
by growth factors and nutrients, and it upregulates anabolic process-
es, such as translation and transcription and blocks catabolic process-
es, like autophagy and apoptosis [22,35,36]. One of the main mTOR
targets is S6 kinase1 which stimulates different stages of protein syn-
thesis, including ribosome biogenesis, initiation and elongation of
translation [23–25]. In this report we show that signal transduction
betweenmTOR and S6K1 is inhibited by SFN.We observed a rapid de-
crease in phosphorylation of S6K1 at threonine 389, a residue phos-
phorylated by mTOR and crucial for S6K1 activation. Subsequent
drop in phosphorylation of ribosomal S6 protein conﬁrms inactiva-
tion of S6 kinase1 (Fig. 2). Lack of S6K1 might be compensated by
other kinases, namely S6K2 or RSK which target serines 235/236 of ri-
bosomal S6 upon activation by mTOR or MAPK, respectively [33]. It is
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revealed upon inhibition of PP1 and PP2A phosphatases (Fig. 3A). Im-
portantly, partial protection against S6 dephosphorylation by 1 nM
calyculin A did not reverse SFN-induced translation inhibition
(Fig. 3B), which strongly suggests that SFN acts upstream of S6. For
instance, targeting S6K1 SFN might inﬂuence different translation
stages. S6K1 phosphorylates and inactivates eEF-2 kinase, which neg-
atively regulates peptide chain elongation. Thus, inhibition of S6K1may lead to premature translation termination [24]. Another, recently
described, S6K1 substrate is a tumor suppressor, programmed cell
death protein 4 (PDCD4). Phosphorylation of PCDC4 by S6K1 leads
to its proteasomal degradation which correlates with cancer progres-
sion and resistance to chemotherapy [37]. PCDC4 negatively regulates
protein synthesis by binding to and inhibiting the helicase activity of
eIF4A, thus impairing the cap-dependent translation [38]. S6K1 also
stimulates eIF4A helicase through phosphorylation and activation of
eIF4B [25]. Thus, SFN-mediated inhibition of S6K1 might negatively
regulate translation initiation. Besides, SFN inhibits mTOR-mediated
phosphorylation of 4E-BP (Fig. 2A and B) which may lead to a block
in a cap-dependent translation.
SFN-induced block in protein synthesis is reversible, at least when
cells are treated for a short time: changing medium after 1.5-hour SFN
treatment for drug-free medium causes gradual re-phosphorylation of
S6K1 and S6. This process, however, is inhibited by rapamycin, which
indicates involvement of mTOR kinase in the signaling. Early removal
of SFN from the medium allows for protein synthesis continuation and
recovery of cell viability to the level characteristic of control cells
(data not shown).
Oxidative stress and dysfunctional mitochondria may inﬂuence
mTOR-S6K1 signaling [39,40]. Earlier studies on mechanisms of SFN
anticancer activity in prostate cancer cells showed that ROS play a
causative role in cell death or cell cycle block, and antioxidants or
overproduction of catalase signiﬁcantly protected cells against these
responses to SFN [12]. The main source of oxidative stress appeared
to be mitochondrial respiratory chain complexes and SFN inhibiting
their activities increased production of ROS [10]. We wondered if a
block in protein synthesis by SFN is mediated by ROS. PC-3 cells
which are devoid of mtDNA (Rho0 cells), thus they have non-
functional respiratory chain, are resistant to SFN-induced oxidative
stress (this work and [10]). However, we observed a protein synthesis
block in Rho0 cells upon SFN treatment. It may indicate that inhibi-
tion of translation by SFN is independent of mitochondria-derived
ROS. SFN-induced oxidative stress in prostate cancer cells is mediated
also by a non-mitochondrial pathway, through glutathione depletion
[12]. Thus, our results do not exclude involvement of mitochondria-
independent ROS in the translation inhibition by SFN. The mechanism
underlying the block in mTOR-S6K signal transduction is currently in-
vestigated but it is not caused by direct inhibition of mTOR catalytic
activity by SFN as judged by in vitro assay (data not shown).
Recent studies demonstrated that translation inhibition is a mech-
anism protecting cells against energetic crisis [41,42]. SFN disturbs
oxidative phosphorylation [10] which might decrease ATP level.
However, we were unable to detect signiﬁcant changes in ATP
concentration in cells treated with SFN for different times (15 min
to 3 h). It is possible that changes in ATP production are too subtle
to be detected by chemiluminescence method or glycolysis is
upregulated and compensates for ATP production. In fact, glycolysis
rate is decreased by SFN, both in PC-3 cells (Fig. 5C) and their Rho0
derivatives (data not shown). We examined the status of AMPK, a
sensitive sensor for cell energetics. It becomes activated by phosphor-
ylation at Thr-172, when AMP:ATP ratio increases in the cells, and
then it inhibits mTOR pathway. In our model AMPK phosphorylation
level rather decreases – statistically signiﬁcant drop is observed after
1 h of SFN treatment (Fig. 5A). Thus, it rather excludes its role in
mTOR-S6K signaling inhibition, which is persistent (Fig. 2A), and in-
dicates that there is no energetic crisis in SFN-treated cells. It is possi-
ble that inhibition of anabolic processes, such as translation (this
work), and activation of catabolic processes, such as autophagy [27],
by SFN allows for maintenance of proper ATP level in cells. Inhibition
of mTOR pathway and protein synthesis, and thus a reduction of en-
ergy consumption, has been recently described as a mechanism
preventing energetic stress in glucose deprived MEF cells [41]. It is
possible that in our model, the inhibition of mitochondrial respiratory
chain enzymes parallels protein synthesis block.
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proteins, crucial for cell viability. One of them is an IAP family mem-
ber, survivin, which regulates cell division, inhibits apoptosis and its
half-life is about 30 min [43]. It is undetectable in majority of normaladult tissues, however it is often overexpressed in tumors, including
prostate cancer [44]. Analysis of clinical samples has shown that ex-
pression of survivin increases from normal prostate tissue to low-
grade primary carcinoma, to high-grade primary carcinoma, and is
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lates with progression of cancer and resistance to therapies [46,47]. Its
expression is regulated at multiple levels. Interestingly, the mTOR-
S6K1 pathway has been shown to regulate stability and translation of
survivin mRNA [48–50]. For instance, it has been shown that insulin
growth factor-1 (IGF-1) induced persistence and translation of a pool
of survivin mRNA in prostate cancer cells and it was mediated by
mTOR-S6K1 [48]. Ablation of endogenous S6K1 by siRNA down-
regulated survivin level [48]. Lowering intracellular survivin levels in
cancer cells has been associated with cell cycle arrest, apoptosis and
sensitization to therapies, thus it was proposed to be a novel cancer-
speciﬁc treatment [51]. Here, we show that survivin level drops upon
SFN treatment in PC-3 cells. Similar effect of SFN on survivin protein
level has been observed in LNCaP and DU145 prostate cancer cells. Au-
thors correlated it with suppression of STAT3 transcription factor by
SFN. However direct link between STAT3 activity and survivin mRNA
or protein level has not been investigated [52]. In our model a drop insurvivin level is concomitantwith translation inhibition and is preceded
by dephosphorylation of S6K1. Moreover, it is not a result of survivin
gene transcription perturbations (Fig. 6B), pointing toward post-
transcriptional regulation. It has been reported that SFN stimulates
ubiquitin–proteasome system activity [53,54]. However, inhibition of
proteasome by MG132 only partially protected against SFN-induced
drop in survivin level, while in control cells led to its accumulation
(Fig. 6C). Thus, all these results indicate that SFN negatively regulates
survivin protein synthesis, rather than accelerates its degradation. A de-
crease in survivin level strongly contributes to SFN anticancer activity as
overproduction of survivin protects against SFN-induced changes in vi-
ability of cells mostly inhibiting apoptosis execution (Fig. 6E–G).
Translation is a vital process, necessary for cell growth and prolif-
eration. Cancer cells worked out mechanisms to sustain this process
at high level, ensuring sufﬁcient levels of nutrients and energy and
upregulating signaling pathways that induce translation. Thus,
targeting synthesis of proteins, especially short-lived ones which are
indispensable for cancer cell survival, might be an important mecha-
nism of SFN chemopreventive and anticancer activity.
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